Bevacizumab

Catalog No.A2006 Synonyms: rhuMab VEGF Non-humanized mouse model applicable

For research use only. Not for use in humans.

Bevacizumab is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Size

Price

Stock

Quantity

5mg	USD 707	In stock
Bulk Size	Bulk Discount

Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck USA Tel: (832) 582-8158 [email protected]

Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description

Bevacizumab is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Targets

VEGF ^[1]
()

In vitro

Gly88 in human VEGF is essential for binding bevacizumab and this residue also underlies the species specificity of bevacizumab binding, since a serine residue is found in mouse and rat VEGF at the corresponding position. In common with its mouse counterpart, bevacizumab binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments. It does not neutralize other members of the VEGF gene family, such as VEGF-B or VEGF-C^[1].

In vivo

The terminal half-life of bevacizumab in humans is 17-21 days. Bevacizumab inhibits the growth of human tumour cell lines in nude mice, achieving a maximal inhibition at the dose of 1-2 mg per kg twice weekly. Half-maximal inhibition requires 0.1-0.5 mg per kg doses. Safety evaluation studies of bevacizumab are conducted in Macaca fascicularis (cynomolgus monkey), a species in which bevacizumab is expected to be pharmacologically active, considering the complete identity between human and cynomolgus VEGF isoforms at the protein level. Following administration of bevacizumab for four or thirteen weeks, young adult cynomolgus monkeys exhibits a physeal dysplasia characterized by a dose-related increase in hypertrophied chondrocytes and inhibition of vascular invasion of the growth plate, which is very similar to the growth-plate lesion observed in mice treated with Flt(1-3)-IgG. Other expected effects of prolonged bevacizumab administration are suppression of angiogenesis in the female reproductive tract, resulting in decreased ovarian and uterine weights, and an absence of corpora lutea. Both the growth-plate and ovarian changes are reversible with cessation of treatment. Importantly, no other treatment-related effects are observed following bevacizumab administration at doses up to 50 mg per kg^[1]. After s.c. administration, rhuMAb VEGF has a bioavailability of 69% in rats and 100% in mice and cynomolgus monkeys. It binds to primate VEGF and with lower affinity to rabbit VEGF but not to rat or mouse VEGF^[2].

Protocol

Cell Research:	+ Expand Objective: Effects of bevacizumab on VEGF-induced HUVEC proliferation Cells: Human umbilical vein endothelial cells (HUVECs) Concentrations: 0~500 ng/mL Incubation Time: 96 h Method: 50 ng/ml of rhVEGF was pre-incubated with a concentration range of bevacizumab (0-500 ng/ml) for 2 h before added to HUVACs. The plate was continuously incubated for 4 days. The proliferation of cells was determined by using Alamar Blue dye. Reference: https://www.ncbi.nlm.nih.gov/pubmed/15886877 Objective: Cell proliferation assay Cells: non small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer (BC) and renal cell carcinoma (RCC) Concentrations: 250 μg/ml Incubation Time: 24, 48, 72 or 96 hours Method: Between 2 × 10³ and 5 × 10³ cells/well (cell line/doubling time dependent) are seeded into 96 well plates and incubated overnight to adhere. Medium is then replaced by RPMI-1640 with reduced FBS and bevacizumab or VEGFA at the concentrations indicated (time point zero). After 24, 48, 72 or 96 hours in hypoxia, MTT (5 mg/ml in PBS) is added and incubated for 2 hours at 37°C. The supernatant is removed and reaction products are solubilized for 1 h in 10% HCl, 0.1% NP-40 in isopropanol. Absorbance is measured at 570 nm with a reference wavelength of 650 nm using an ELISA reader. Each experimental condition is analyzed in triplicate and results are an average of a minimum of three biological repetitions. Reference: https://www.ncbi.nlm.nih.gov/pubmed/24059699 Bevacizumab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)
Animal Research:	+ Expand Objective: To determine the antitumor response of bevacizumab and cisplatin as single agents or in combination in xenograft models of ovarian cancer Animal Models: Nude mice were injected (i.p.) with 5×10⁶ A2780 cells Formulation: PBS Dosages: 5mg/kg Administration: i.p. Reference: https://www.ncbi.nlm.nih.gov/pubmed/19047105 Objective: To determine the pharmacokinetics of bevacizumab Animal Models: Female nude mice Formulation: -- Dosages: 9.3 mg/kg Administration: i.v. or s.c. injection Reference: https://www.ncbi.nlm.nih.gov/pubmed/9862791 Bevacizumab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

Cell Research:

+ Expand

Objective: Effects of bevacizumab on VEGF-induced HUVEC proliferation
Cells: Human umbilical vein endothelial cells (HUVECs)
Concentrations: 0~500 ng/mL
Incubation Time: 96 h
Method: 50 ng/ml of rhVEGF was pre-incubated with a concentration range of bevacizumab (0-500 ng/ml) for 2 h before added to HUVACs. The plate was continuously incubated for 4 days. The proliferation of cells was determined by using Alamar Blue dye.
Reference: https://www.ncbi.nlm.nih.gov/pubmed/15886877

Objective: Cell proliferation assay
Cells: non small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer (BC) and renal cell carcinoma (RCC)
Concentrations: 250 μg/ml
Incubation Time: 24, 48, 72 or 96 hours
Method: Between 2 × 10³ and 5 × 10³ cells/well (cell line/doubling time dependent) are seeded into 96 well plates and incubated overnight to adhere. Medium is then replaced by RPMI-1640 with reduced FBS and bevacizumab or VEGFA at the concentrations indicated (time point zero). After 24, 48, 72 or 96 hours in hypoxia, MTT (5 mg/ml in PBS) is added and incubated for 2 hours at 37°C. The supernatant is removed and reaction products are solubilized for 1 h in 10% HCl, 0.1% NP-40 in isopropanol. Absorbance is measured at 570 nm with a reference wavelength of 650 nm using an ELISA reader. Each experimental condition is analyzed in triplicate and results are an average of a minimum of three biological repetitions.
Reference: https://www.ncbi.nlm.nih.gov/pubmed/24059699

Bevacizumab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

Animal Research:

+ Expand

Objective: To determine the antitumor response of bevacizumab and cisplatin as single agents or in combination in xenograft models of ovarian cancer
Animal Models: Nude mice were injected (i.p.) with 5×10⁶ A2780 cells
Formulation: PBS
Dosages: 5mg/kg
Administration: i.p.
Reference: https://www.ncbi.nlm.nih.gov/pubmed/19047105

Objective: To determine the pharmacokinetics of bevacizumab
Animal Models: Female nude mice
Formulation: --
Dosages: 9.3 mg/kg
Administration: i.v. or s.c. injection
Reference: https://www.ncbi.nlm.nih.gov/pubmed/9862791

Bevacizumab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

References

Product Details

Formulation	PBS buffer, pH 7.2
Isotype	Human IgG
Source	CHO cells
Storage	Store at -80°C and avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

VEGFR Signaling Pathway Map

Related VEGFR Products

SU5402 ^New

SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
Regorafenib (BAY 73-4506)

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Axitinib

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Features:Superior as second-line therapy relative to sorafenib (current standard-of-care).
Cabozantinib (XL184, BMS-907351)

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.
Nintedanib (BIBF 1120)

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.
Vandetanib (ZD6474)

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM.
Lenvatinib (E7080)

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.
Pazopanib

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type